Stay updated on Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-05-01T23:52:06.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new version of the study protocol and includes the name of the principal investigator, Corey Langer, MD, at the Abramson Cancer Center. Additionally, the specific study identifier UPCC 25514 has been added.
    Difference
    50%
    Check dated 2025-04-17T11:13:01.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to January 22, 2025.
    Difference
    0.4%
    Check dated 2025-04-10T06:27:53.000Z thumbnail image
  5. Check
    36 days ago
    No Change Detected
  6. Check
    72 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-02-25T19:12:25.000Z thumbnail image
  7. Check
    86 days ago
    Change Detected
    Summary
    The web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    1%
    Check dated 2025-02-11T10:05:48.000Z thumbnail image
  8. Check
    94 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.1 to 2.14.2.
    Difference
    0.1%
    Check dated 2025-02-04T05:48:41.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.